Overview

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Status:
Completed
Trial end date:
2017-07-17
Target enrollment:
Participant gender:
Summary
To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
Phase:
Phase 3
Details
Lead Sponsor:
AMAG Pharmaceuticals, Inc.
Treatments:
Ferric Compounds
Ferrosoferric Oxide
Iron